Korsana Biosciences, Inc. (KRSA) - Guggenheim 3rd Annual Healthcare Innovation Conference - KORSANA BIOSCIENCES INC

Financial Performance:

• Raised approximately $500 million in capital to date.
• Entered public markets a few months prior to the call.
• No specific revenue, earnings, or profit margin figures disclosed as the company is pre-commercial/clinical-stage; focus is on development spend rather than commercial revenue.

Guidance and Future Outlook:

• Plans to file a Clinical Trial Application (CTA) for the Single Ascending Dose (SAD) portion of the Phase 1/2 study by the end of the current year.
• Aims to file an Investigational New Drug (IND) application early next year to initiate Multiple Ascending Dose (MAD) studies in patients.
• Targeting preliminary efficacy data (interim proof of concept) in the middle of next year.
• Goal to design a Phase 1/2 study that is Phase 3-enabling, potentially allowing a direct transition to pivotal trials if safety and efficacy metrics are met.
• Long-term objective is to achieve a monthly, low-volume subcutaneous (SC) autoinjector formulation for home administration.

Business Segments and Product Lines:

• Lead Asset (KRS-028): A blood-brain barrier shuttle antibody targeting pyroglutamate-modified forms of amyloid (plaque-selective).
• Differentiation Strategy:
  • Utilizes "selective effector function modulation" via FC engineering: preserves phagocytosis (plaque clearance) while eliminating Complement-Dependent Cytotoxicity (CDC) and Antibody-Dependent Cellular Cytotoxicity (ADCC).
  • Designed to improve peripheral exposure and half-life to allow lower, less frequent dosing compared to existing IV therapies.
  • Specifically engineered to avoid the reticulocyte depletion and anemia observed with Roche's Leqembi (Leqembi/trontinamab).
• Formulation: Developing as a subcutaneous product from the outset, designed for high concentration and low viscosity to facilitate monthly injections.
• Licensing: Program licensed from Paragon Therapeutics.
• Pipeline Focus: Laser-focused on KRS-028; not currently expanding into multiple new programs but open to exploring other neurodegenerative targets (e.g., Tau) post-amyloid success.

Market and Competitive Landscape:

• Target Market: Alzheimer's disease, viewed as a massive, expanding opportunity similar to the Multiple Sclerosis market evolution, with a patient population 6-7x larger.
• Competitive Context:
  • Acknowledges Leqembi (Lilly) and Kisunla (Roche) as current standards that prove biology but have limitations (IV administration, infusion reactions, anemia).
  • Views the market as capable of supporting multiple winners, with KRS-028 aiming for a "best-in-class" profile.
  • Mentions AbbVie/Aliata's shuttle program (no effector function) as a competitor lacking phagocytosis support, creating uncertainty on their efficacy.
• Market Trends: Shift from IV to subcutaneous administration and increased focus on improving safety (lower ARIA risk) and convenience (monthly home dosing).

Risks and Challenges:

• Safety (ARIA): Amyloid-Related Imaging Abnormalities (ARIA) remain a key concern; the company aims for single-digit ARIA rates, comparable to Leqembi, but acknowledges this risk persists in APOE4 homozygous patients.
• Anemia: Mitigating reticulocyte depletion (a known issue with earlier shuttle technologies and Leqembi) is a critical challenge; preclinical data in non-human primates suggests success, but clinical confirmation is pending.
• Clinical Success: Uncertainty remains on whether faster plaque clearance (achieved via improved exposure) translates to superior clinical efficacy compared to existing therapies.
• Regulatory: Must secure global regulatory buy-in for a streamlined Phase 1/2 to Phase 3 transition based on integrated data.

Management Commentary and Tone:

• Tone: Highly confident and optimistic, emphasizing the "inflection point" in Alzheimer's treatment and the significant unmet need.
• Confidence: Management expresses strong confidence in the "selective effector function" approach, citing clinically validated FC engineering techniques.
• Focus: Emphasizes speed and efficiency, aiming to bring a best-in-class SC product to market quickly to capitalize on the massive addressable market.
• Strategy: Rejects the "platform company" model, favoring a deep, focused development path for a single, high-potential asset to maximize value creation.

Analyst Questions and Answers:

• Q: Why subcutaneous formulation? A: To improve patient convenience and caregiver burden; requires specific protein engineering for high concentration/low viscosity.
• Q: How does exposure benefit differ from Leqembi? A: While Leqembi clears plaques quickly (3-6 months), improved exposure in KRS-028 may allow similar clearance with lower/fewer doses; ultimate clinical speed of clearance is unknown but hypothesized to be faster.
• Q: Why no anemia with KRS-028? A: Preclinical NHP data shows elimination of acute reticulocyte depletion via CDC/ADCC elimination; Leqembi still shows 10-20% anemia rates.
• Q: What defines success in Phase 1/2? A: Demonstration of robust plaque clearance via PET tracers at a dose matching Leqembi, with ARIA rates in the single-digit percentage and standard safety profile.
• Q: Will ARIA monitoring burden be reduced? A: Initial protocols will likely match current standards (multiple MRIs in first 6 months), but long-term data may support reduced monitoring frequency.
• Q: Are APOE4 carriers included? A: Yes, "all comers" will be enrolled without bias to allow direct comparison with Leqembi data, though APOE4 status will be tracked.

Other Key Points:

• The company views the Alzheimer's market as having "waves of entrance" similar to Multiple Sclerosis, where incremental improvements lead to a dominant product.
• Management believes the current approved therapies (Kisunbi, Leqembi) are merely the "first steps" and that significant room exists for improvement in safety and delivery.
• The company intends to keep the specific FC mutations proprietary until patents publish but asserts the technology is not novel in isolation, but novel in combination.
• AbbVie's acquisition of Aliata's shuttle program is noted as a key event to watch, though data is not yet fully public.